Phase II Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)
Summary
This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
General Information
NCT#: NCT03891784
Study ID: RG1004456
Trial Phase: Phase II
Trial Sponsor: National Cancer Institute (NCI), Eli Lilly, University of Washington
Therapies Used in This Trial: Abemaciclib